Kidney International reports on a series of systemic lupus erythematosus (SLE) patients, who despite inactive urinary sediment and low level proteinuria, had a high rate of glomerulonephritis (GN) proven by renal biopsy; moreover, the LN was not predicted by laboratory abnormalities.
Acute gout has its well defined protocols, and most state that urate lowering therapy (ULT) should be continued; but does ULT affect outcomes in an acute gout attack?
Read Article
2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related. Below, are our top news items
Read Article
The ProDERM study design and outcomes are previewed in Medicine; and as promised the results were revealed at ACR Convergence in November 2020 showing that IVIg is safe, effective and superior to placebo i(PBO) in patients with dermatomyositis (DM).
Read Article
MMWR has reported on a July 2020 survey study from 1,009 Health Resources and Services Administration–funded health centers showing that urban Health centers were more likely to provide virtual visits than those in rural areas.
Telehealth has expanded healthcare access, especially in
Read Article
There have been conflicting reports of whether rheumatic patients have greater risks once they are infected with COVID-19. This claims cohort analysis suggests a mixed picture.
Read Article
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
Read Article
2020 evidence-based clinical practice guideline for the prevention, diagnosis, and treatment of Lyme disease was cooperatively developed the Infectious Diseases Society of America (IDSA), the American Academy of Neurology (AAN), and the American College of Rheumatology (ACR). The guideline
Read Article
Dr Jack Cush takes questions from RheumNow listeners
The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020. Watch now!
Bella Mehta bella_mehta ( View Tweet)
k dao KDAO2011 ( View Tweet)
Eric Dein ejdein1 ( View Tweet)
Dr Jack Cush overviews the RheumNow commitment, upcoming bonus coverage of ACR20 and the good news and journal reports from the past week on RheumNow.com
Read Article
A full read review of immune-mediated necrotizing myopathy is portrayed as a distinct subtype of inflammatory myopathies first described in 2004.
This form of myositis has been associated with antibodies to signal recognition particle (anti-SRP) or anti-3-hydroxy-3-methylglutaryl-coA
Read Article
Dr. Jack Cush reviews the news, journal reports, survey results and "Back Talk" questions from Rheums.
Read Article
The FDA has approved Gilead Sciences Inc’s antiviral drug remdesivir for treating patients hospitalized with COVID-19, making it the first and only drug approved for the disease in the United States.
FDA approved its 1st drug to treat COVID-19 -
Read Article
Dr. Jack Cush sings the news and journal reports from the past week on RheumNow.com.
Read Article
NEJM reports the results of the SELECT-Choice trial, a head to head study of upadacitinib (UPA) and abatacept (ABA) in biologic refractory rheumatoid arthritis (RA); 12 weeks results showed UPA was significantly more clinically effective than ABA using a DAS28-CRP remission, but ABA had fewer
Read Article
A large RA cohort study from the Swedish Rheumatology Quality Register shows a higher risk of venous thromboembolism (VTE) in rheumatoid arthritis (RA) and that risk is linked to RA disease activity.
Read Article
Two biologic therapies showed promise in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (EGPA) in a retrospective European study.
Among 63 patients who were treated with rituximab (Rituxan), remission or partial responses at 1 year were observed
Read Article
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. Regulatory approvals, update on global rheumatology alliance, smoking and psoriasis, gabapentin let down and defining difficult RA.
